Obesity Clinical Trial
Official title:
Fecal Microbial Transplantation and Fiber Supplementation in Subjects With Obesity and Metabolic Syndrome
This study is looking at the safety and effectiveness of stool transplant, also known as
Fecal Microbiota Transplantation (FMT) and prebiotic supplementation in the management of
metabolic syndrome.
Metabolic syndrome is a common progressive medical condition that is linked to obesity,
diabetes, and heart disease. Obesity and metabolic syndrome are associated with abnormalities
in gut flora which lead to chronic inflammation. This chronic inflammation is thought to
worsen the insulin resistance and heart disease seen with metabolic syndrome. Current
treatment strategies have shown limited effect, are expensive, and have side effects with
long-term use.
FMT is a one-time treatment that has been shown to replace the abnormal gut flora and improve
metabolic disease by increasing anti-inflammatory short chain fatty acid (SCFA) production.
However, the effects from FMT are not permanent. Prebiotic supplementation is one strategy
that may help to extend the benefits of FMT by helping sustain high SCFA levels. At this
point, it is not known how FMT and prebiotics work together to affect SCFA levels in
participants with metabolic syndrome.
This study will look at this interaction and answer if prebiotic therapy is effective in
prolonging the benefits of FMT in participants with metabolic syndrome.
3.0 Design This is an exploratory four-arm, parallel design, randomized placebo-controlled
intervention study in obese individuals with metabolic syndrome to evaluate whether FMT from
lean donors combined with supplementation with prebiotic fiber will have a clinically
significant effect on metabolic parameters. The study includes a 2-week screening/baseline
period followed by a single FMT and a 6 week study period in which prebiotic fiber or placebo
will be added in powdered form to the subject's normal diet for the duration of the trial
(Appendix 1). A follow-up visit at 12 weeks will be done to determine if beneficial effects
are maintained in the absence of ongoing fiber intake. A parallel arm design was chosen to
avoid cross-over effects.
The four groups are:
1. Control (Placebo FMT and cellulose)
2. FMT only (FMT followed by cellulose)
3. Prebiotic only (Placebo FMT and prebiotic fiber)
4. FMT + prebiotic fiber Schedule and Procedures: Subjects will attend a total of 5 clinic
appointments throughout the study for anthropometric and blood pressure measurements,
dietary intake, hunger and satiety, and quality of life assessment using questionnaires,
and for collection of blood and fecal samples (Appendix 2). The intervention will be
stopped at 6 weeks. A final follow-up visit will occur at 12 weeks for anthropometric
and blood pressure measurements, and collection of blood and stool samples.
3.1 Randomization Subjects will be randomized to one of 4 groups via computer-generated
numbers and stratified by gender. Individuals will be blinded as to their group allocation to
reduce bias. Randomization concealment will be protected by several levels of security,
including our secure website, password protection by only those authorized to randomize and a
variable blocked randomization.
3.2 Maintenance
Randomized codes will be maintained in REDCAP. Codes will be broken at the end of the trial.
3.3 Trial Treatment
Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be
administered in 20-30 capsules taken by mouth. These capsules will be frozen at -700C until
date of administration on day 1 of the trial. The FMT will be given after individuals have
fasted overnight and completes a bowel preparation using Pico-Salax®, a routine colonoscopy
preparation. The study will use only one donor to reduce variability in donor profiles unless
this donor becomes unavailable at which point backup donors will be available. Placebo FMT
will consist of cellulose pills.
Fiber Supplementation:
Soluble corn fiber (PROMITOR®: Tate&Lyle)
- Women: 4.5 gm of PROMITOR by mouth days 1-3 increased to 9 gm daily from day 4 until
trial completion.
- Men: 5.5 gm of PROMITOR by mouth days 1-3 increased to 11 gm by mouth daily from day 4
until trial completion.
Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients):
- Women: 4.5 gm of powdered RS4 by mouth days 1-3 increased to 9 gm by mouth daily from
day 4 until trial completion.
- Men: 5.5gm of powdered RS4 by mouth days 1-3 increased to 11 gm by mouth daily from day
4 until trial completion.
Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS):
- Women: 4.5 gm of powdered acacia gum by mouth days 1-3 increased to 9 gm by mouth daily
from day 4 until trial completion.
- Men: 5.5gm of powdered acacia gum by mouth days 1-3 increased to 11 gm by mouth daily
from day 4 until trial completion.
The product will be supplied to patients on a weekly basis in pre-weighed foil packets.
Placebo: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in
identical foil packets.
3.4 Duration
The study duration is 12 weeks. Subjects will be seen in the clinic at recruitment, and then
at 2 and 6 weeks following FMT. Intervention will be from 1-6 weeks. A final follow-up visit
will occur at 12 weeks (Appendix 1)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |